Quintiles VP of strategic business and oncology operations, Christopher Ung, sat down with Outsourcing-pharma recently to review the importance of biomarkers in cancer drug development. Fewer than one in 10 NMEs in the oncology realm actually reach the market while six out of 10 late-stage cancer drug trials fail. Report